{"name":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","slug":"hangzhou-acea-pharmaceutical-research-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Abivertinib Maleate Capsules","genericName":"Abivertinib Maleate Capsules","slug":"abivertinib-maleate-capsules","indication":"Non-small cell lung cancer with EGFR mutations","status":"phase_3"},{"name":"Placebo Gefitinib Tablets","genericName":"Placebo Gefitinib Tablets","slug":"placebo-gefitinib-tablets","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Abivertinib Maleate Capsules","genericName":"Abivertinib Maleate Capsules","slug":"abivertinib-maleate-capsules","phase":"phase_3","mechanism":"Abivertinib is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation.","indications":["Non-small cell lung cancer with EGFR mutations"],"catalyst":""},{"name":"Placebo Gefitinib Tablets","genericName":"Placebo Gefitinib Tablets","slug":"placebo-gefitinib-tablets","phase":"phase_3","mechanism":"Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.","indications":["Non-small cell lung cancer","Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5HWnFGa3pSWGtjWDJrNmtlZ1Y0QnVVcUd5UGJmWndURmlVRTNVdm1MX09EZVlrOFR5SzJhdFNzQlVpeXp3YnJIb0VyZ0prZm5oMXNHa2p0S3FXYUpDeVkw?oc=5","date":"2017-06-30","type":"pipeline","source":"Nature","summary":"0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop - Nature","headline":"0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}